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Key Points
• The JAK2/STAT5 pathway is
a relevant therapeutic target
in CML SPCs.
• Targeting the JAK2/STAT5
pathway by nilotinib and RUX
in combination leads to
enhanced eradication of
primitive CML stem cells.
Chronicmyeloid leukemia (CML) stem cell survival is not dependent onBCR-ABLprotein
kinase and treatment with ABL tyrosine kinase inhibitors cures only a minority of CML
patients, thus highlighting the need for novel therapeutic targets. The Janus kinase
(JAK)2/signal transducer and activator of transcription (STAT)5 pathway has recently
beenexplored forprovidingputativesurvival signals toCMLstem/progenitor cells (SPCs)
with contradictory results. We investigated the role of this pathway using the JAK2
inhibitor, ruxolitinib (RUX). We demonstrated that the combination of RUX, at clinically
achievableconcentrations,with thespecificandpotent tyrosinekinase inhibitornilotinib,
reduced the activity of the JAK2/STAT5 pathway in vitro relative to either single agent
alone. These effects correlated with increased apoptosis of CML SPCs in vitro and a
reduction in primitive quiescent CML stemcells, includingNOD.Cg-Prkdcscid IL2rgtm1Wjl /SzJ
mice repopulating cells, induced by combination treatment. A degree of toxicity toward
normal SPCs was observed with the combination treatment, although this related to mature B-cell engraftment in NOD.Cg-Prkdcscid
IL2rgtm1Wjl /SzJ mice with minimal effects on primitive CD341 cells. These results support the JAK2/STAT5 pathway as a relevant
therapeutic target in CML SPCs and endorse the current use of nilotinib in combination with RUX in clinical trials to eradicate
persistent disease in CML patients. (Blood. 2014;124(9):1492-1501)
Introduction
Chronic myeloid leukemia (CML) arises in a hemopoietic stem cell
(HSC) as a result of the reciprocal translocation between chromo-
somes 9 and 22 (t9;22), leading to the formation of the fusion oncogene
BCR-ABL. The BCR-ABL protein has constitutive tyrosine kinase
(TK) activity which drives myeloid progenitor cell expansion and is
both necessary and sufﬁcient for the transformed phenotype.1 The
introduction of ABL TK inhibitors (TKI) has dramatically changed
themanagement of newlydiagnosed chronic phase (CP)CMLpatients,
with the vast majority now achieving deep molecular responses,
while enjoying a good quality of life.2 However, 15% to 20% of
patients show variable degrees of resistance to currently available
TKI,3 and even in patients achieving deep responses, including those
with undetectable BCR-ABL transcript levels, there is evidence of
persistence of BCR-ABL1 cells at the stem-cell level4,5 and of posi-
tivity for BCR-ABL genomic DNA by polymerase chain reaction
(PCR).6,7 Furthermore, over 50% of patients achieving sustained
undetectable BCR-ABL transcript levels showed evidence of mo-
lecular relapse upon TKI discontinuation.8 Leukemic stem cell
(LSC) persistence determines the need for lifelong TKI treatment
in the ever growing CML patient population, with associated
implications in terms of compliance, adverse events, and costs. Recent
evidence has demonstrated that CML-LSC persistence is secondary
to their insensitivity to TKI despite effective BCR-ABL kinase
inhibition, suggesting that other pathways contribute to their
survival.9,10 Identifying such pathways and trying to exploit them
therapeutically is paramount to achieving CML-LSC eradication
and disease cure.
During normal hemopoiesis, the intracellular TK Janus kinase
(JAK)2 is activated following binding of hemopoietic growth factors
(GF) to their receptors. JAK2 subsequently phosphorylates the signal
transducer and activator of transcription (STAT)5 factor, leading to
its nuclear relocation. Nuclear STAT5 exerts its activity by regulating
the transcription of genes involved in normal hemopoiesis.11 The
central role of the JAK2/STAT5 axis is clearly demonstrated by the
profound effects on hemopoiesis, resulting in embryonic lethality of
JAK2 knockout (KO) mice.12-14 Both JAK2 and STAT5 are consti-
tutively active in BCR-ABL1 cells15,16 with evidence supporting a
role for each in CML leukemogenesis. BCR-ABL1 cell clones
transfected with kinase inactive JAK2 mutant displayed reduced
clonogenic potential and tumorogenic activity.17 Recently, the existence
Submitted December 19, 2013; accepted June 16, 2014. Prepublished online
as Blood First Edition paper, June 23, 2014; DOI 10.1182/blood-2013-12-
545640.
The online version of this article contains a data supplement.
There is an Inside Blood Commentary on this article in this issue.
The publication costs of this article were defrayed in part by page charge
payment. Therefore, and solely to indicate this fact, this article is hereby
marked “advertisement” in accordance with 18 USC section 1734.
© 2014 by The American Society of Hematology
1492 BLOOD, 28 AUGUST 2014 x VOLUME 124, NUMBER 9
For personal use only.on December 19, 2014. by guest  www.bloodjournal.orgFrom 
of a JAK2/BCR-ABL protein complex, which helps to stabilize BCR-
ABL kinase activity, has been demonstrated.18,19 Disrupting this
complex using either JAK2 chemical inhibitors or RNA interference
was shown to increase eradication of BCR-ABL1 cells, including
primary CMLCD341 cells.18,20 Similarly, STAT5-deletedmurine bone
marrow (BM) cells transduced with BCR-ABL retrovirus were unable
to generate and maintain BCR-ABL1 leukemias in vivo.21-23
Furthermore, high levels of STAT5 were protective for BCR-ABL1
cells treated with TKI24 and speciﬁc targeting of STAT5 activity
increased eradication of BCR-ABL1 cells, including primary CML
CD341 cells and CML cells resistant to TKI.25 Pharmacologic
interferencewith the JAK2/STAT5pathway, therefore, represents an
attractive therapeutic strategy inCML; however, STAT5 is a difﬁcult
drug target as it lacks an enzymatic domain and a simpler approach to
interferewith STAT5 function is to inhibit its predominant activating
kinase, JAK2.
In contrast to normal hemopoiesis, the role of JAK2 in activating
STAT5 in BCR-ABL1 leukemias remains controversial. Investiga-
tions using both a dominant negative JAK2mutant26 and BCR-ABL
transduced JAK2KOmurine BMcells27 suggested that BCR-ABL is
able to directly phosphorylate STAT5, rendering the role of JAK2
dispensable. It has also been suggested that the reported effects of
most JAK2 inhibitors on BCR-ABL1 cells were secondary to their
off-target inhibition of BCR-ABL kinase.27,28 These data have ques-
tioned the role of JAK2 as a bona ﬁde therapeutic target in CML.
The relevance of understanding the role of the JAK/STATpathway
in CML has increased with the clinical development of numerous
JAK2 inhibitors. Among these, ruxolitinib (RUX) has emerged as a
potent and orally bioavailable JAK1/2 inhibitor29 which is now
licensed for the treatment of primarymyeloﬁbrosis following results
from phase 3 clinical trials.30,31 As a result, a therapeutic strategy
employing RUX in CML could now easily be pursued, and early
phase clinical studies aiming to assess the ability of RUX and TKI
in combination, to eradicate CML stem/progenitor cells (SPCs) are
already underway (ClinicalTrials.gov identiﬁers: #NCT01702064
and #NCT01751425). In this study, we aimed to further characterize
the role of JAK2 in human primary CMLCD341 cells and complemen-
tary mouse models. The effects of RUX alone and in combination
with nilotinib (NL) on JAK2 and STAT5 activity were assessed,
aiming to clarify whether JAK2 modulated STAT5 activity in CML
cells, especially in the context of a fully inhibited BCR-ABL kinase.
Moreover, the effects of RUX, with or without NL, on the survival
and proliferation of primary humanCD341CMLand normal cells in
vitro and on leukemia engraftment in vivo, were tested to assess their
efﬁcacy in CML and potential toxicity to normal cells.
Methods
Reagents
RUXandNLwere supplied byNovartis Pharmaceuticals and stored at 10mM
in dimethylsulfoxide at220°C.
Primary cell samples and in vitro culture
Primary cells were obtained following consent, according to the Declaration
of Helsinki, from peripheral blood leukapheresis samples of newly diagnosed
CP CML patients (see supplemental Table on the BloodWeb site) and lym-
phoma patients without BM involvement or cord blood (CB) as normal
controls. Enrichment for CD341 expression, ﬂuorescence-activated cell sorting
(FACS) of CMLCD341CD382, detection ofBCR-ABL fusion in CMLSPC/
LSC cells by ﬂuorescence in situ hybridization (FISH), and in vitro culture
in physiological (CML/CB) or high (adult normal CD341) GF-supplemented
serum-free mediumwere conducted, as previously reported.9,32 Total cell
counts were performed using the trypan blue dye exclusion method or
CountBright Absolute Counting Beads for ﬂow cytometry (Life Technolo-
gies). Storage and use of primary cell samples for research purposes was
approved byWest of ScotlandResearchEthicsCommittee 4 (ref #10/S0704/2).
Colony-forming cell assays, apoptosis assessment, and cell
division tracking
Colony-forming cell (CFC) assays, apoptosis measurement by Annexin-V
staining, and cell division tracking using carboxyﬂuorescein diacetate
succinimidyl ester (CFSE; Life Technologies) of CML and normal CD341
cells were performed according to standard protocols, as previously
described.9
Engraftment of human cells in immunodeficient mice
CML CD341 cells (13 106 cells/mouse) or CB CD341 cells (13 105 cells/
mouse) were cultured for 72 hours in the absence of drug (control), or with
addition of NL (1mM) alone, RUX (500 nM) alone, or their combination. Cells
were then harvested, washed, and transplanted via tail vein injection into sub-
lethally irradiated (300 cGy) 8-week-old NOD. Cg-Prkdcscid IL2rgtm1Wjl /SzJ
(NSG) mice (The Jackson Laboratory). Mice were euthanized after 16 (CB)
and 18 (CML) weeks and marrow contents of femurs, spleen cells, and blood
cells were obtained at necropsy. To assess human cell engraftment, cells were
labeled with antihuman CD45-allophycocyanin antibody (#17-9459-42; eBio-
science) and analyzed by ﬂow cytometry. Speciﬁc human cell subsets were
detected by staining with antibodies to human CD34-PE-Cy7 (#25-0349-42;
eBioscience), CD33-PE (#347787; BD Biosciences), and CD19-eﬂuoro450
(#48-0199-42; eBioscience). Human CD451 cells were selected by immuno-
magnetic column selection. To assess engraftment of malignant BCR-ABL
expressing cells, CD451 selected cells were evaluated forBCR-ABLmessenger
RNA (mRNA) levels by quantitative reverse-transcription PCR (qRT-PCR)
using custom made primers and probes for both BCR-ABL (forward primer
GGGCTCTATGGGTTTCTGAATG; reverse primer CGCTGAAGGGCT
TTTGAACT; probe CATCGTCCACTCAGCCACTGGATTTAAGC), and
BCR (forwardprimerCCTTCGACGTCAATAACAAGGAT; reverse primer
CCTGCGATGGCGTTCAC; and probe TCCATCTCGCTCATCATCACC
GACA) as the reference gene.
FACS and western blotting
FACS for intracellular protein staining andwestern blot analysiswas performed
as previously reported32 using the following antibodies: p-JAK2Tyr1007/1008
(#1477-1) (Epitomics), p-STAT5Tyr694 (#9351), p-CrkLTyr207 (#3181),
p-c-AblTyr245 (#2868), and b-tubulin (#2128) (New England BioLabs),
SH-PTP2 (#sc-280) (Santa Cruz Biotechnology).
RNA extraction, complementary DNA synthesis, and qRT-PCR
Total RNA was isolated from pellets using the RNeasy Mini Kit (Qiagen,
United Kingdom) according to the manufacturer’s instructions. complemen-
taryDNA (cDNA) was generated using the High Capacity cDNA Reverse
Transcription Kit and speciﬁc target ampliﬁcation was performed using
the TaqMan PreAmp Master Mix Kit (Life Technologies) according
to manufacturer’s protocol. qRT-PCR was performed using the Fluidigm
BioMark HD System with the following TaqMan validated gene ex-
pression assays: BCL-XL (Hs01067345_g1); BCL6 (Hs00277037_m1);
Cyclin D1 (Hs00765553_m1); Cyclin D2 (Hs00277041_m1); Cyclin
D3 (Hs00426901_m1); CDKN1B/p27 (Hs00153277_m1); GAPDH
(Hs99999905_m1); ID1 (Hs03676575_s1);MYC (Hs00905030_m1); PTEN
(Hs03673482_s1); and TBP (Hs99999910_m1).
Statistical analysis
All data from independent experiments are presented as mean 6 standard
error of the mean (SEM). Statistical analyses were performed using the paired
Student t test formatched samples, theMann-Whitney test for unpaired samples,
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and the one-way ANOVA with post hoc testing for multiple comparisons.
P # .05 was considered statistically signiﬁcant.
Results
The combination of NL and RUX deeply inhibits JAK2
and STAT5 activities, with no off-target effects on
BCR-ABL kinase
To assess the respective activities of JAK2 and STAT5 in CML
CD341 cells following treatment with NL or RUX or both, levels
of p-JAK2 and p-STAT5 were measured by ﬂow cytometry over
72 hours of culture in medium supplemented with physiological GFs
to mimic microenvironmental signaling.33 Interestingly, while both
p-JAK2 and p-STAT5 levels were reduced by NL treatment, which
infers that both are partially regulated by BCR-ABL kinase, the
addition of RUX caused a faster and deeper reduction in the level of
both phosphoproteins (Figure 1A-B and supplemental Figure 1A).
Further evidence of this more pronounced inhibition of STAT5
activity by the combination treatment was derived by gene expression
analysis of several STAT5 target genes. Treatment with the combined
agents, as compared with NL or RUX alone, caused further down-
regulation of genes known to be positively regulated bySTAT5, such
as the antiapoptotic gene BCL-XL, the positive cell cycle regulators
Cyclin D1, D2, D3,MYC, and the transcription factor ID1,34 which
plays a key role in HSC self-renewal and differentiation.35,36
Conversely, genes normally negatively regulated by STAT5 were
upregulated, including the negative regulator of the AKT pathway,
PTEN, the negative regulator of cell cycle, CDKN1B/p27, and the
transcription factor, BCL6, which has been reported to be important
for themaintenance ofCMLLSC37 (Figure 1C).When these cultures
were repeated in the absence of paracrine GFs, the enhanced STAT5
inhibition with the combination was no longer observed (supple-
mental Figure 1B).
Figure 1. Effects of the NL and RUX combination on JAK2/STAT5 signaling. CML CD341 samples (n 5 3) were either left untreated (UT), or treated with NL (5 mM) or
RUX (200 nM) or their combination. After 24 hours of incubation in suspension cultures, p-STAT5Tyr694 (A) and p-JAK2Tyr1007/1008 (B) levels were measured by intracellular
flow cytometry. Levels of phosphorylation of both proteins were expressed as a ratio of the mean fluorescence intensity of p-STAT5Tyr694 (A) and p-JAK2Tyr1007/1008 (B)
antibody stained cells over the mean fluorescence intensity of cells stained with a matched isotype control. The average of UT values was normalized to 100% and changes
following treatment expressed as % change from UT. (C) Candidate STAT5 target genes mRNA expression changes were measured in CML CD341 samples (n 5 5)
following 8 hours in suspension culture with NL (5 mM) or RUX (1000 nM), or their combination. Differences in gene expression levels following treatment were calculated
using the 22DDCt method after normalization within each sample of candidate gene expression levels against the expression levels of the reference genes (GAPDH and TBP).
Relative quantitation of candidate genes mRNA expression following NL, and NL and RUX treatment, was then plotted as log2 of the 2
2DDCt values (with the RUX-treated cells
having a value of 0 in the graph and being the calibrator). All data from independent experiments are presented as mean 6 SEM. Significance values: *P , .05; †P , .01;
‡P , .001. ns, not significant.
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Analysis of the phosphorylation levels ofBCR-ABLand its kinase
substrate CrkL demonstrated that full inhibition of BCR-ABL
kinase activity had been achieved upon treatment with NL. No
signiﬁcant changes in neither p-BCR-ABL nor p-CrkL levels
were observed when cells were treated with RUX as a single agent
(Figure 2A-B). These data eliminate any concerns that the additive
effects on STAT5 signaling of the combined inhibitor treatment were
secondary to RUX-induced off-target effects on BCR-ABL kinase
activity, as had been suggested for other JAK2 inhibitors and for RUX
at higher concentrations (.20 mM).27
Overall, these data showed that the combination of NL and RUX
caused a more rapid and profound inhibition of p-STAT5 activity as
compared with single agents and that this was not secondary to off-
target effects of the JAK2 inhibitor on BCR-ABL kinase activity.
The combination of NL and RUX increases kill and reduces CFC
output of human CML CD341 cells, while sparing normal
CD341 cells in vitro
Given the additive effects of NL in combination with RUX on STAT5
signaling, the biological effects of these agents against primary
CML CD341 cells were investigated in vitro. Following preliminary
experiments to establish the IC50 of RUX in this cell population
(supplemental Figure 2), a concentration of 200 nM was selected.
This concentration was commensurate with that used in published
preclinical studies of cell lines harboring the JAK2V617F mutation29
and below the maximal concentration of 1000 nM achieved in the
plasma of patients treated with currently licensed doses of RUX.38
Moreover, this concentration was 100-fold less than the RUX con-
centration reported to produce off-target effects onBCR-ABLkinase.27
While neither NL or RUX showed limited effects on CML CD341
cell viability, their combination induced higher levels of apoptosis
(Figure 3A). Similarly, while RUX had no effect and NL reduced
CML CD341 CFC output by 47% relative to starting CFC output
(baseline), their combination produced a further 49% reduction in
the total number of CFC produced relative to NL as a single agent
(Figure 3B). Similar effects were seen for both erythroid and
granulocyte-macrophage colonies (Figure 3C-D), and NL and RUX
combinedwere alsonoted to reduce the size of the colonies (Figure 3E).
Interestingly, these effects were not observed when CML CD341
cells were grown in the absence of any GFs (supplemental Figure 3).
A similar series of experiments was then performed using normal
CD341 cells to determine if there was a selectivity toward CML
CD341 cells over normal SPC for the drug combination. Following
combination treatment, apoptosis levels were only mildly, and not
signiﬁcantly, increased for the combination vs each single agent
and this did not translate to a signiﬁcant reduction in normal CFC
output (Figure 3F-G). Overall, these data showed that the combination
of NL and RUX was more effective than NL treatment alone in
eradicating CML CD341 cells, including CFC, in short term culture
assays. These effects were observed only in the presence of GFs.
Although a degree of toxicity toward mature normal progenitors was
observed, this was less marked than for CML CD341.
The combination of NL and RUX increases the kill of human
CML CD341 CD382 and CFSEmax cells while sparing
primitive normal CD341 cells in vitro
In order to assess the effects of the NL and RUX combination on a
more primitive population of CML and normal SPC, cell division
tracking experiments using CFSE staining were performed. These
conﬁrmed a marked effect on CML CD341 cell proliferation with
the combination treatment, with a reduction in undivided CFSEmax,
slowly proliferating (division 1), and the total number of CD341
cells recovered (Figure 4A-B). These effects were paralleled by an
increase in apoptosis levels within the CFSEmax population with the
combination treatment comparedwith either single agent (Figure 4C).
Conversely, similar experiments on normal CD341 cells conﬁrmed a
slight antiproliferative effect for the combination treatment; however,
in contrast to results for CML, there was no signiﬁcant reduction in
the total number of normal CD341 cells recovered over 72 hours, and
in particular, there was no signiﬁcant reduction in the CFSEmax
population (Figure 4D-E). Nor was there a signiﬁcant increase in
apoptosis levels within the CFSEmax population (Figure 4F). Finally,
similar additive effects were also observed following NL and RUX
combination treatment on sorted populations of CML (BCR-ABL1
by FISH) CD341CD382 cells, which are known to be enriched for
the most primitive, quiescent population39 (Figure 4G). Taken
together, these data showed that NL and RUX in combination,
caused a more profound effect on the quiescent stem-cell com-
partment compared with either agent alone while appearing to
spare the normal quiescent fraction.
The combination of NL and RUX selectively eliminates NSG
repopulating CML cells
The effects of NL and RUX, alone and combined, were compared
against primaryCMLand normal SPC inNSG transplantation assays
(Figure 5A). CD341 cells treated with NL, RUX, or the combination
were injected into NSG mice and engraftment was evaluated. We
chose this exvivo treatment approach sinceCMLCPcells demonstrate
relatively poor engraftment and do not develop leukemia in NSG
mice which limits the feasibility of in vivo drug treatment studies to
evaluate the effects of treatment on leukemia development and
survival. Following 72 hours drug exposure, reconstitution of human
CD451 hemopoiesis by CML CD341 cells was signiﬁcantly reduced
by either RUX or NL alone; however, the combination of NL with
RUX induced a more profound reduction of short-term (6 weeks)
and long-term (18 weeks) engraftment of CML cells in NSG mice
(supplemental Figure 4 and Figure 5B). In particular, both CD341
cell engraftment andmyeloid engraftmentwere signiﬁcantly reduced
by the combination treatment (Figure 5C). Moreover, qRT-PCR
analysis showed that the reduction in humanCD451 cell engraftment
correlated with a reduction of BCR-ABL levels in residual cells
Figure 2. Effects of the NL and RUX combination on BCR-ABL kinase activity.
CML CD341 cells were either left UT, or treated for 8 hours with NL (5 mM) or RUX
(1000 nM) or their combination, prior to protein extraction and measurement of (A)
p-BCR-ABL (p-c-AblTyr245) (n 5 2), and (B) p-CrkLTyr207 (n 5 4, 2 representative blots
shown) levels by western blot. SH-PTP2 (A) and b-tubulin (B) were used as loading controls.
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(Figure 5D). Similar experiments performed using CD341 cells
derived from normal human CB showed that both NL alone, and
the NLwith RUX combination, reduced the reconstitution of total
humanCD451 hemopoietic cells (supplemental Figure 5).However,
subset analysis conﬁrmed that the reduction in engraftment was
restricted to CD191 B cells with no such effect on either CD341 or
CD331 myeloid cell engraftment. The reduction in B-cell engraft-
ment was driven by NL and not further affected by the addition of
RUX (Figure 5E).
Overall, these results showed that the combination of NL and
RUX reduced the transplantable leukemogenic activity of CML
CD341 cells more effectively than either agent alone, while having
Figure 3. Effects of the NL and RUX combination on CML and normal CD341 cell viability and CFC output. (A) CML CD341 cells (n 5 3) were either left UT, or
treated with NL (5 mM) or RUX (200 nM) or their combination, and cultured. At 48 hours, apoptosis levels were measured by Annexin-V/7AAD staining. CML CD341
cells (n 5 3) were cultured as in (A) for 72 hours before drug washout and plating in methylcellulose progenitor assays. (B) Total CFC output was recorded after
12 days culture and compared with the CFC output for each sample prior to the start of the culture (baseline) (note that the number of colonies following 72 hours
culture was adjusted for the expansion of CD341 cells in vitro in each arm relative to baseline). (C) CFC frequency based on their morphology (erythroid-burst
forming unit and erythroid-colony forming unit), and (D) granulocyte/macrophage-colony forming unit was also recorded and again compared with baseline. (E)
Representative pictures of the size and morphology of recovered CFC in each treatment arm. Normal CD341 cells (n 5 3) were either left UT, or treated with NL
(5 mM) or RUX (200 nM) or their combination. (F) At 48 hours, apoptosis levels were measured by Annexin-V/7AAD staining. Normal CD341 cells (n 5 3) were
cultured as in (A) for 72 hours before drug washout and plating in methylcellulose progenitor assays. (G) Total CFC output was recorded after 12 days culture and
compared with the CFC output at baseline as explained in (B). All data from independent experiments are presented as mean 6 SEM. Significance values: *P , .05;
†P , .01; ‡P , .001.
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Figure 4. Effects of the NL and RUX combination on primitive and quiescent (CFSEmax) CML and normal CD341 cells. (A) CML and (B) normal CD341 cells (n 5 3)
were stained with CFSE and either left UT, or treated with NL (5 mM) or RUX (200 nM) or their combination, and cultured. At 72 hours, the percentage of starting CD341 cells
recovered within each division in each treatment arm was calculated by recording the number of viable cells seeded initially in each culture and their number following different
treatment conditions. Levels of CFSE fluorescence was used to measure the percentage of cells within each division as explained previously.32 (C) Percentage of total
number of starting CML, and (D) normal CD341 cells recovered in each arm following treatment was also recorded at 72 hours. Percentage of apoptotic cells within the
undivided (CFSEmax) population was measured by gating on the population double-positive for maximal CFSE expression, and Annexin-V staining at 72 hours for both (E)
CML and (F) normal CD341 cells. (G) Sorted CML, BCR-ABL1 (by FISH) CD341 CD382 cells (n 5 3) were cultured as in (A) for 72 hours. Percentage of viable cells was
measured by gating on the double-negative population following Annexin-V/DAPI staining. The results were then normalized against UT within each sample. All data from
independent experiments are presented as mean 6 SEM. Significance values: *P , .05; †P , .01; ‡P , .001.
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no signiﬁcant effects on normal human CD341 and myeloid cell
engraftment.
Discussion
The development of JAK2 inhibitors available for clinical inves-
tigation has opened up an exciting potential avenue to explore in
CML, however, further clariﬁcation of the role of JAK2 in this
disease is required before pursuing it as a legitimate therapeutic
target. In this study, we have provided preclinical evidence for
effective targeting of JAK2 in CMLCD341 cells using the inhibitor
RUX, by showing a consistent reduction in viability, colony output,
and proliferation of CML CD341 cells, including the quiescent
fraction, in vitro and reduced engraftment of CMLCD341 cells in
vivo, when treated with NL and RUX compared with NL treatment
alone. Interestingly, the effects of RUX as a single agent weremodest,
but became more dramatic when combined with NL, suggesting that
the role of JAK2 is particularly prominent during TKI therapy and
that CML CD341 cells become more reliant on JAK2 kinase when
BCR-ABL is fully inhibited. These ﬁndings are consistent with those
published recently byother research groups,mainly using nonclinically
developed JAK2 inhibitors,40-43 but are contrary to those reported by
Hantschel et al, showing that BCR-ABL is still able to transform
murine BMcells in which JAK2 has been deleted, both in vitro and in
vivo.27Moreover, a recent report suggested that JAK2 deletionmight
accelerate CML development in mouse models by preferentially
causing elimination of normal HSC which are more dependent on
JAK2 signaling compared with CML LSC where BCR-ABL is
active.13 This discrepancymight be explained by the fact that the role
of JAK2 may indeed be dispensable when BCR-ABL is fully active,
but becomes critical when BCR-ABL kinase is inhibited as has also
been shown for other potential targets.37 Only upon inhibition of
BCR-ABL do these targets become relevant, thus explaining the
need to continue TKI together with any novel therapeutic agent to
eradicate CML LSC, despite the evidence that CML LSC are not
BCR-ABL kinase dependent for their survival.9,10 Moreover, in the
report by Hantschel et al, a different model was employed (BCR-
ABL transduced murine BM cells vs primary CP CML cells,
Figure 5. Effects of NL and RUX combination on the transplantable leukemogenic activity of CML CD341 cells and on normal CB CD341 cell engraftment. (A)
Experimental design for the in vivo experiments. CML CD341 cells (from 2 patients) or human CB CD341 cells (from 2 subjects) were cultured for 72 hours with either NL (1 mM)
or RUX (500 nM) or their combination, or media control. Following treatment, recovered cells were washed and injected intravenously into 8-week-old, sublethally irradiated
(300 cGy) NSG mice (CML, 5 mice/per group; CB, 4 mice for controls; RUX, 4; NL, 5; and NL1RUX, 5). (B) The levels of human CML CD451 cells, and (C) CD341, CD331,
and CD191 cells regenerated in the BM of mice transplanted with cells treated in different conditions were measured at 18 weeks. (D) The levels of BCR-ABLmRNA within the
human CML CD451 selected cells obtained from mouse BM at 18 weeks were evaluated by qRT-PCR and normalized to BCR mRNA expression levels. (E) The levels of
human CB CD341, CD331, and CD191 cells regenerated in the BM of mice transplanted with cells treated in different conditions were measured at 16 weeks. All data
from independent experiments are presented as mean 6 SEM. Significance values: *P , .05; †P , .01; ‡P , .001.
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respectively, with the former likely expressing higher levels of BCR-
ABL compared with the latter), and most of their in vitro work was
performed in the absence of exogenous GFs. We also noted that when
RUXandNLwere combined inCMLcells grown in the absenceofGFs,
the additional effects of the JAK2 inhibitor were abolished, suggesting
that one of the main roles of JAK2, independent of BCR-ABL kinase
and in the presence of NL, is to relay survival signals from exogenous
GFs which can be effectively inhibited by RUX, as also previously
reported.40-43 This further helps to resolve the discrepancy between our
ﬁndings and those of Hantschel et al. Our data therefore, suggested that
in the absence of GFs, JAK2 signals were either absent or under the
direct control of BCR-ABL, hence completely abrogated by the high
doses of NL used in our experiments. Based on our data, one of the
putative mechanisms of action of theNL andRUX combination in the
presence of exogenous GFs was a more profound inhibition of JAK2/
STAT5 activity, as shown by the correlative changes in both p-JAK2
and p-STAT5 levels, with combined treatment, associated with
correlative changes in STAT5 target genes. This was not due to off-
target inhibition of BCR-ABL kinase by RUX, as has been shown for
other JAK2 inhibitors,27 and we were careful to use RUX at
concentrations well below those previously shown to potentially
cause off-target inhibition of BCR-ABL kinase (ie, more than 20
mM).27 Moreover, achieving further inhibition of BCR-ABL
kinase activity by adding RUX was highly unlikely in our
experimental setting as the NL concentration used was shown to
achieve maximal BCR-ABL kinase inhibition. In summary, we
conclude that enhanced inhibition of STAT5 activity by the NL
and RUX combination was one of the major mechanisms under-
lying the effects seen.
However, alternative modes of action for the NL and RUX
combination, independent of STAT5 activation, are possible.
Although we deliberately chose NL for this study as the most
speciﬁc BCR-ABL kinase inhibitor available, we cannot exclude
that additional NL targets are important and required for the observed
additive effects. Similarly, JAK2 has also been shown to have other
targets than STAT5. It directly phosphorylates BCR-ABL on its key
residue tyrosine 17720 (which is central for its transforming capacity
through its ability to activate both the RAS/MAP kinase and the
PI3 kinase pathways44-46), and functions as a histone kinase and
chromatin modiﬁer47 while also being able to activate MYC48 and
b-catenin.49 This last effect is particularly relevant given the central
role of b-catenin in CML LSC self-renewal50-52 and might explain
the effects of RUX on the most primitive population, including
CFSEmax,CD341CD382, andNSGrepopulating cells,which support
those already reported by others using different, not clinically
developed, JAK2 inhibitors.49 Finally, it should also be considered
that RUX is a potent inhibitor of JAK1 and other oncogenic kinases
at the concentrations used,28 and therefore, some of the effects seen
could be mediated independently of JAK2.28 In this respect, other
reports on the efﬁcacyofRUX(andother JAK inhibitors) inBCR-ABL
positive cells have shown inhibition of STAT3 activity (a down-
stream target of JAK1/2) as a possiblemechanism-of-action for these
agents.41,42 All the above might explain why the effects seen in
functional assays are greater than the ones seen on the JAK2/STAT5
pathway when using RUX alone. Future work will clarify if these or
other unknown mechanisms-of-action of JAK2 are present in CML
SPC,whichmight account for the effects seen here in functional assays.
One of themain concerns for the use of JAK2 inhibitors inCML is
their potential toxicity to normal BM, following a report showing
toxicity of several JAK2 inhibitors toward normal hemopoiesis.41
Despite its apparently narrow therapeutic window, our in vitro and in
vivo data reassuringly showed that a strategy combining RUX and
NL preferentially eradicated CML compared with normal CD341
cells, when a carefully selected concentration of RUX was chosen.
The reason behind the increased sensitivity of TKI-treated CML vs
normal SPCs to JAK2 inhibition is currently unclear. We speculate
that in CML SPCs, the prior expression of BCR-ABL may alter
signaling networks such that cells are dependent on higher levels of
GFs signaling activity, possibly due to upregulation or enhanced
activity of cytokine receptors as shown already in both CML53,54 and
acutemyeloid leukemiamodels.55 UponBCR-ABL inhibition, these
cells may therefore be dependent on higher levels of GF-mediated
JAK2/STAT5 activation for continued viability as compared with
normal cells. Moreover, it is reassuring that RUX has been used as
a single agent for the treatment of patients with myeloﬁbrosis,30,31
with no severe BM toxicity experienced, especially for patients with
good BM reserve, which is the prevailing situation in CP CML
patients with minimal residual disease on TKI. This suggests that the
BM toxicity secondary to JAK2 inhibition in adults might be less
than that observed during embryonic development in JAK2 KO
mice.12-14 This is to be expected given that chemical inhibition is
less complete than gene deletion and evidence that JAK2 scaffolding
functions, which would not be targeted by a JAK2 kinase inhibitor,
might be important for its activity.56 In conclusion, our work
supports a role for JAK2 in primaryCMLSPC survival, and provides
further preclinical evidence for studies combining TKI with RUX
in CML patients. We also provide evidence of a role for JAK2 in
activating STAT5-dependent survival signals in CML CD341 cells,
upon BCR-ABL kinase inhibition and in the presence of GFs, thus
explaining the observed efﬁcacy of JAK2 inhibitors. We, therefore,
believe that in CMLpatients withminimal residual disease who have
optimally responded toTKI therapy, additional therapeutic strategies
targeting JAK2, in combination with TKI, warrant investigation in
an attempt to achieve disease eradication.
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